The development of site-specific drug delivery nanocarriers based on receptor mediation

Journal of Controlled Release

Volumn 193, Issue , 2014, Pages 139-153

  Wang, Xueqing ^a   Li, Suxin ^a   Shi, Yujie ^a   Chuan, Xingxing ^a   Li, Ji ^a   Zhong, Ting ^a   Zhang, Hua ^a   Dai, Wenbing ^a   He, Bing ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Multi targeting system; Nanocarriers; Non therapeutic targets; Receptor mediation; Site specific drug delivery; Therapeutic targets

Indexed keywords

NANO-CARRIERS; RECEPTOR MEDIATION; SITE-SPECIFIC DRUG DELIVERIES; TARGETING SYSTEMS; THERAPEUTIC TARGETS;

NANOCARRIER; ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; DRUG CARRIER; LIGAND; NANOPARTICLE; PROTEIN BINDING;

ANTIGENICITY; ARTICLE; BIOTECHNOLOGY; CANCER CELL; CANCER INHIBITION; CELL POPULATION; DRUG DELIVERY SYSTEM; IN VIVO STUDY; MOLECULAR WEIGHT; NANOTECHNOLOGY; ANIMAL; CHEMISTRY; DRUG DESIGN; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; NANOPARTICLES; PROTEIN BINDING; RECEPTORS, CELL SURFACE;

EID: 84908262658     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.05.028     Document Type: Article

References (180)

1. N. Kamaly, Z. Xiao, P.M. Valencia, A.F. Radovic-Morenob, and O.C. Farokhzad Targeted polymeric therapeutic nanoparticles: design, development and clinical translation Chem. Soc. Rev. 41 2012 2971 3010
2. K. Strebhardt, and A. Ullrich Paul Ehrlich's magic bullet concept: 100 years of progress Nat. Rev. Cancer 8 2008 473 480
3. S. Svenson Clinical translation of nanomedicines Curr. Opin. Solid State Mater. Sci. 16 2012 287 294
4. R. van der Meel, L.J.C. Vehmeijer, R.J. Kok, G. Storm, and E.V. van Gaal Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status Adv. Drug Deliv. Rev. 65 2013 1284 1298
5. C.R. Behrens, and B. Liu Methods for site-specific drug conjugation to antibodies MAbs. 6 2013 46 53
6. N.K. Mehra, V. Mishra, and N.K. Jain Receptor-based targeting of therapeutics Ther. Deliv. 4 2013 369 394
7. J. Nicolas, S. Mura, and D. Brambilla Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery Chem. Soc. Rev. 42 2013 1147 1235
8. J.O. Olsen, R.V. Pozderac, G. Hinkle, T. Hill, T.M. O'Dorisio, W.J. Schirmer, E.C. Ellison, and M.S. O'Dorisio Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan) Semin. Nucl. Med. 25 1995 251 261
9. N.M. Barkey, N.K. Tafreshi, and J.S. Josan Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand J. Med. Chem. 54 2011 8078 8084
10. M. Mammen, S.K. Choi, and G.M. Whitesides Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors Angew. Chem. Int. Ed. 37 1998 2754 2794
11. Y. Lu, and P.S. Low Folate-mediated delivery of macromolecular anticancer therapeutic agents Adv. Drug Deliv. Rev. 54 2002 675 693
12. P.S. Low, and S.A. Kularatne Folate-targeted therapeutic and imaging agents for cancer Curr. Opin. Chem. Biol. 13 2009 256 262
13. R.J. Lee, and P.S. Low Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro Biochim. Biophys. Acta 1233 1995 134 144
14. W.H. Chiang, W.C. Huang, C.W. Chang, M.Y. Shen, Z.F. Shih, Y.F. Huang, S.C. Lin, and H.C. Chiu Functionalized polymersomes with outlayered polyelectrolyte gels for potential tumor-targeted delivery of multimodal therapies and MR imaging J. Control. Release 168 2013 280 288
15. L.Y. Qiu, L. Yan, L. Zhang, Y.M. Jin, and Q.H. Zhao Folate-modified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery Int. J. Pharm. 456 2013 315 324
16. J. Pang, L. Zhao, and L. Zhang Folate-conjugated hybrid SBA-15 particles for targeted anticancer drug delivery J. Colloid Interface Sci. 395 2013 31 39
17. J. Zhou, J. Wang, Q. Xu, S. Xu, J. Wen, Z. Yu, and D. Yang Folate-chitosan-gemcitabine core-shell nanoparticles targeted to pancreatic cancer Chin. J. Cancer Res. 25 2013 527 535
18. R. Wittig, J.M. Rosenholm, E. von Haartman, J. Hemming, F. Genze, L. Bergman, T. Simmet, M. Lindén, and C. Sahlgren Active targeting of mesoporous silica drug carriers enhances γ-secretase inhibitor efficacy in an in vivo model for breast cancer Nanomedicine 2013 10.2217/NNM.13.62
19. J. Yang, Z. Wang, and S. Zong Dual-mode tracking of tumor-cell-specific drug delivery using fluorescence and label-free SERS techniques Biosens. Bioelectron. 51 2014 82 89
20. Q. Zeng, H. Wen, and Q. Wen Cucumber mosaic virus as drug delivery vehicle for doxorubicin Biomaterials 34 2013 4632 4642
21. Y. Furusho, M. Miyata, T. Matsuyama, T. Nagai, H. Li, Y. Akasaki, N. Hamada, T. Miyauchi, Y. Ikeda, T. Shirasawa, K. Ide, and C. Tei Novel therapy for atherosclerosis using recombinant immunotoxin against folate receptor β-expressing macrophages J. Am. Heart Assoc. 1 2012 e003079 10.1161/JAHA.112.003079
22. B. Varghese, N. Haase, and P.S. Low Depletion of folate-receptor-positive macrophages leads to alleviation of symptoms and prolonged survival in two murine models of systemic lupus erythematosus Mol. Pharm. 4 2007 679 685
23. B.R. Bozard, P.P. Chothe, A. Tawfik, C. Williams, S. Fulzele, P.D. Prasad, P.M. Martin, V. Ganapathy, and S.B. Smith Regulation of proton-coupled folate transporter in retinal Müller cells by the anti-psoriatic drug monomethylfumarate Glia 60 2012 333 342
24. T.P. Thomas, S.N. Goonewardena, I. Majoros, A. Kotlyar, Z. Cao, P.R. Leroueil, and J.R. Baker Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis Arthritis Rheum. 63 2011 2671 2680
25. P.M. Valencia, M.H. Hanewich-Hollatz, W. Gao, F. Karim, R. Langer, R. Karnik, and O.C. Farokhzad Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles Biomaterials 32 2011 6226 6233
26. Z. Qian, H. Li, H. Sun, and K. Ho Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway Pharmacol. Rev. 54 2002 561 587
27. I. Nakase, H. Lai, N.P. Singh, and T. Sasaki Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation Int. J. Pharm. 354 2008 28 33
28. C. Dufès, M. Al Robaian, and S. Somani Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells Ther. Deliv. 4 2013 629 640
29. W. Du, Y. Fan, N. Zheng, B. He, L. Yuan, H. Zhang, X. Wang, J. Wang, X. Zhang, and Q. Zhang Transferrin receptor specific nanocarriers conjugated with functional 7 peptide for oral drug delivery Biomaterials 34 2013 794 806
30. L. Tavano, R. Muzzalupo, L. Mauro, M. Pellegrino, S. Andò, and N. Picci Transferrin-conjugated pluronic niosomes as a new drug delivery system for anticancer therapy Langmuir 29 2013 12638 12646
31. J.P. Nam, S.C. Park, T.H. Kim, J.Y. Jang, C. Choi, M.K. Jang, and J.W. Nah Encapsulation of paclitaxel into lauric acid-O-carboxymethyl chitosan-transferrin micelles for hydrophobic drug delivery and site-specific targeted delivery Int. J. Pharm. 457 2013 124 135
32. S.D. Mahajan, I. Roy, G. Xu, K.T. Yong, H. Ding, R. Aalinkeel, J.L. Reynolds, D.E. Sykes, B.B. Nair, E.Y. Lin, P.N. Prasad, and S.A. Schwartz Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles Curr. HIV Res. 8 2010 396 404
33. L. Han, R. Huang, S. Liu, S. Huang, and C. Jiang Peptide-conjugated pamam for targeted doxorubicin delivery to transferrin receptor overexpressed tumors Mol. Pharm. 7 2010 2156 2165
34. V. Mishra, S. Mahor, A. Rawat, P. Gupta, P. Dubey, K. Khatri, and S.P. Vyas Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles J. Drug Target. 14 2006 45 53
35. Y.N. Konan, R. Gurny, and E. Allémann State of the art in the delivery of photosensitizers for photodynamic therapy J. Photochem. Photobiol. B 66 2002 89 106
36. P.C.N. Rensen, R.L.A. de Vrueh, J. Kuiper, M.K. Bijsterbosch, E.A.L. Biessen, and T.J.C. van Berkel Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting Adv. Drug Deliv. Rev. 47 2001 251 276
37. B. Zhang, X. Sun, H. Mei, Y. Wang, Z. Liao, J. Chen, Q. Zhang, Y. Hu, Z. Pang, and X. Jiang LDLR-mediated peptide-22-conjugated nanoparticles for dualtargeting therapy of brain glioma Biomaterials 34 2013 9171 9182
38. J. Varshosaz, F. Hassanzadeh, H. Sadeghi, and S. Andalib Synthesis of octadecylamine-retinoic acid conjugate for enhanced cytotoxic effects of 5-FU using LDL targeted nanostructured lipid carriers Eur. J. Med. Chem. 54 2012 429 438
39. V. Huntosova, D. Buzova, D. Petrovajova, P. Kasakc, Z. Nadova, D. Jancura, F. Sureau, and P. Miskovsky Development of a new LDL-based transport system for hydrophobic/amphiphilic drug delivery to cancer cells Int. J. Pharm. 436 2012 463 471
40. P.I. Kitov, J.M. Sadowska, and G. Mulvey Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands Nature 403 2000 669 672
41. S. Arpicco, G.D. Rosa, and E. Fattal Lipid-based nanovectors for targeting of cd44-overexpressing tumor cells J. Drug Deliv. 2013 860780
42. K.K. Upadhyay, A.K. Mishra, K. Chuttani, A. Kaul, C. Schatz, J.F.L. Meins, A. Misra, and S. Lecommandoux The in vivo behavior and antitumor activity of doxorubicin-loaded poly(γ-benzyl l-glutamate)-block-hyaluronan polymersomes in Ehrlich ascites tumor-bearing BalB/c mice Nanomedicine 8 2012 71 80
43. Z. Chen, Z. Li, Y. Lin, M. Yin, J. Ren, and X. Qu Biomineralization inspired surface engineering of nanocarriers for pH-responsive, targeted drug delivery Biomaterials 34 2013 1364 1371
44. M. Yu, S. Jambhrunkar, P. Thorn, J. Chen, W. Gu, and C. Yu Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells Nanoscale 5 2013 178 183
45. M.H. El-Dakdouki, E. Puré, and X. Huang Development of drug loaded nanoparticles for tumor targeting. Part 2: Enhancement of tumor penetration through receptor mediated transcytosis in 3D tumor models Nanoscale 5 2013 3904 3911
46. J.-H. Park, H.-J. Cho, H.Y. Yoon, I.-S. Yoon, S.-H. Ko, J.-S. Shim, J.-H. Cho, J.H. Park, K. Kimh, I.C. Kwon, and D.-D. Kima Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery J. Control. Release 174 2014 98 108
47. G. Ashwell, and J. Harford Carbohydrate-specific receptors of the liver Annu. Rev. Biochem. 51 1982 531 554
48. Chittima Managit, Shigeru Kawakami, Fumiyoshi Yamashita, and M. Hashida Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes J. Pharm. Sci. 94 2005 2266 2275
49. X. Zhang, X. Zhang, P. Yu, Y. Han, Y. Li, and C. Li Hydrotropic polymeric mixed micelles based on functional hyperbranched polyglycerol copolymers as hepatoma-targeting drug delivery system J. Pharm. Sci. 102 2013 145 153
50. X. Zhou, M. Zhang, B. Yung, H. Li, C. Zhou, L.J. Lee, and R.J. Lee Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma Int. J. Nanomedicine 7 2012 5465 5474
51. Y. Xiao, H. Zhang, Z. Zhang, M. Yan, M. Lei, K. Zeng, and C. Zhao Synthesis of novel tetravalent galactosylated DTPA-DSPE and study on hepatocyte-targeting efficiency in vitro and in vivo Int. J. Nanomedicine 8 2013 3033 3050
52. C. Duan, J. Gao, D. Zhang, L. Jia, Y. Liu, D. Zheng, G. Liu, X. Tian, F. Wang, and Q. Zhang Galactose-decorated ph-responsive nanogels for hepatoma-targeted delivery of oridonin Biomacromolecules 12 2011 4335 4343
53. Z. Shena, W. Wei, H. Tanaka, K. Kohama, G. Ma, T. Dobashi, Y. Maki, H. Wang, J. Bi, and S. Dai A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy Pharm. Res. 64 2011 410 419
54. Z. Wen, Z. Yan, K. Hu, Z. Pang, X. Cheng, L. Guo, Q. Zhang, X. Jiang, L. Fang, and R. Lai Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration J. Control. Release 151 2011 131 138
55. C. Bies, C.M. Lehr, and J.F. Woodley Lectin-mediated drug targeting: history and applications Adv. Drug Deliv. Rev. 56 2004 425 435
56. T. Minko Drug targeting to the colon with lectins and neoglycoconjugates Adv. Drug Deliv. Rev. 56 2004 491 509
57. M.A. Jepsona, M.A. Clark, and B.H. Hirst M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery Adv. Drug Deliv. Rev. 56 2004 511 525
58. J.D. Smart Lectin-mediated drug delivery in the oral cavity Adv. Drug Deliv. Rev. 56 2004 481 489
59. Y. Liu, P. Wang, C. Sun, J. Zhao, Y. Du, F. Shi, and N. Feng Bioadhesion and enhanced bioavailability by wheat germ agglutinin-grafted lipid nanoparticles for oral delivery of poorly water-soluble drug bufalin Int. J. Pharm. 419 2011 260 265
60. L. Neutsch, E.M. Wirth, S. Spijker, C. Pichl, H. Kählig, F. Gabor, and M. Wirth Synergistic targeting/prodrug strategies for intravesical drug delivery - lectin-modified PLGA microparticles enhance cytotoxicity of stearoyl gemcitabine by contact-dependent transfer J. Control. Release 169 2013 62 72
61. A. Singh, F. Dilnawaz, and S.K. Sahoo Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy PLoS ONE 6 2011 e26803
62. J. Chen, C. Zhang, Q. Liu, X. Shao, C. Feng, Y. Shen, Q. Zhang, and X. Jiang Solanum tuberosum lectin-conjugated PLGA nanoparticles for nose-to-brain delivery: in vivo and in vitro evaluations J. Drug Target. 20 2012 174 184
63. H.L. Goel, and A.M. Mercurio VEGF targets the tumour cell Nat. Rev. Cancer 13 2013 871 882
64. L. Brannon-Peppas, and J.O. Blanchette Nanoparticle and targeted systems for cancer therapy Adv. Drug Deliv. Rev. 64 2012 206 212
65. A.P. Janssen, R.M. Schiffelers, T.L. Ten Hagen, G.A. Koning, A.J. Schraa, R.J. Kok, G. Storm, and G. Molema Peptide-targeted PEG-liposomes in anti-angiogenic therapy Int. J. Pharm. 254 2003 55 58
66. D.H. Yu, Q. Lu, J. Xie, C. Fang, and H.Z. Chen Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature Biomaterials 31 2010 2278 2292
67. C. Kim, H. Yang, Y. Fukushima, P.E. Saw, J. Lee, J.S. Park, I. Park, J. Jung, H. Kataoka, D. Lee, W.D. Heo, I. Kim, S. Jon, R.H. Adams, S. Nishikawa, A. Uemura, and G.Y. Koh Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption Cancer Cell 25 2014 102 117
68. M. Wickström, R. Larsson, P. Nygren, and J. Gullbo Aminopeptidase N (CD13) as a target for cancer chemotherapy Cancer Sci. 102 2011 501 508
69. X. Wang, Y. Wang, X. Chen, J. Wang, X. Zhang, and Q. Zhang NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells J. Control. Release 139 2009 56 62
70. F. Pastorino, C. Brignole, D. Marimpietri, M. Cilli, C. Gambini, D. Ribatti, R. Longhi, T.M. Allen, A. Corti, and M. Ponzoni Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy Cancer Res. 63 2003 7400 7409
71. B.J. Zhao, X.Y. Ke, Y. Huang, X.M. Chen, X. Zhao, B.X. Zhao, W.L. Lu, J.N. Lou, X. Zhang, and Q. Zhang The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats J. Drug Target. 19 2011 382 390
72. L.M. Luo, Y. Huang, B.X. Zhao, X. Zhao, Y. Duan, R. Du, K.F. Yu, P. Song, Y. Zhao, X. Zhang, and Q. Zhang Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel Biomaterials 34 2013 1102 1114
73. A.H. Negussie, J.L. Miller, G. Reddy, S.K. Drake, B.J. Wood, and M.R. Dreher Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome J. Control. Release 143 2010 265 273
74. G. Colombo, F. Curnis, G.M.S. De Mori, A. Gasparri, C. Longoni, A. Sacchi, R. Longhi, and A. Corti Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif J. Biol. Chem. 277 2002 47891 47897
75. A. Corti, and M. Ponzoni Tumor vascular targeting with tumor necrosis factor α and chemotherapeutic drugs Ann. N. Y. Acad. Sci. 1028 2004 104 112
76. S. Dedhar Integrins and signal transduction Curr. Opin. Hematol. 6 1999 37
77. F. Danhier, A.L. Breton, and V. Préat RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis Mol. Pharm. 9 2012 2961 2973
78. U.K. Marelli, F. Rechenmacher, T.R. Sobahi, C. Mas-Moruno, and H. Kessler Tumor targeting via integrin ligands Front. Oncol. 3 2013 222
79. R.M. Schiffelers, G.A. Koning, T.L. ten Hagen, M.H. Fens, A.J. Schraa, A.P. Janssen, R.J. Kok, G. Molema, and G. Storm Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin J. Control. Release 91 2003 115 122
80. P.K. Dubey, V. Mishra, S. Jain, S. Mahor, and S.P. Vyas Liposomes modified with cyclic RGD peptide for tumor targeting J. Drug Target. 12 2004 257 264
81. X.B. Xiong, Y. Huang, W.L. Lu, X. Zhang, H. Zhang, T. Nagai, and Q. Zhang Intracellular delivery of doxorubicin with RGD modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo J. Pharm. Sci. 94 2005 1782 1793
82. L. Ma, Y.L. Liu, Z.Z. Ma, H.L. Dou, J.H. Xu, J.C. Wang, X. Zhang, and Q. Zhang Targeted treatment of choroidal neovascularization using integrin-mediated sterically stabilized liposomes loaded with combretastatin A4 J. Ocul. Pharmacol. Ther. 25 2009 195 200
83. Y. Wang, X. Wang, Y. Zhang, S. Yang, J. Wang, X. Zhang, and Q. Zhang RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells J. Drug Target. 17 2009 459 467
84. Y. Wang, T. Yang, X. Wang, J. Wang, X. Zhang, and Q. Zhang Targeted polymeric micelle system for delivery of combretastatin A4 to tumor vasculature in vitro Pharm. Res. 27 2010 1861 1868
85. Y. Zhang, F. Zheng, T. Yang, W. Zhou, Y. Liu, N. Man, L. Zhang, N. Jin, Q. Dou, Y. Zhang, Z. Li, and L.P. Wen Tuning the autophagy-inducing activity of lanthanide-based nanocrystals through specific surface-coating peptides Nat. Mater. 11 2012 817 826
86. F. Danhier, B. Vroman, N. Lecouturier, N. Crokart, V. Pourcelle, H. Freichels, C. Jérôme, J. Marchand-Brynaert, O. Feron, and V. Préat Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel J. Control. Release 140 2009 166 173
87. X.B. Xiong, Y. Huang, W. Lu, H. Zhang, X. Zhang, and Q. Zhang Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo Pharm. Res. 22 2005 933 939
88. X.B. Xiong, Y. Huang, W.L. Lu, X. Zhang, H. Zhang, T. Nagai, and Q. Zhang Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic J. Control. Release 107 2005 262 275
89. J. Yin, Z. Li, T. Yang, J. Wang, X. Zhang, and Q. Zhang Cyclic RGDyK conjugation facilitates intracellular drug delivery of polymeric micelles to integrin-overexpressing tumor cells and neovasculature J. Drug Target. 19 2011 25 36
90. C.B. Pattillo, F. Sari-Sarraf, R. Nallamothu, B.M. Moore, G.C. Wood, and M.F. Kiani Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay Pharm. Res. 22 2005 1117 1120
91. X.B. Xiong, A. Mahmud, H. Uludag, and A. Lavasanifar Conjugation of arginine-glycine-aspartic acid peptides to poly (ethylene oxide)-b-poly (ε-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells Biomacromolecules 8 2007 874 884
92. P. Hölig, M. Bach, T. Völkel, T. Nahde, S. Hoffmann, R. Müller, and R.E. Kontermann Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells Protein Eng. Des. Sel. 17 2004 433 441
93. W. Dai, T. Yang, X. Wang, J. Wang, X. Zhang, and Q. Zhang PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells J. Drug Target. 18 2010 254 263
94. 1, antagonist targets stealth liposomes to integrin-overexpressing melanoma Nanomedicine 8 2012 1152 1161
95. S.M. Huang, and P.M. Harari Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results Investig. New Drugs 17 1999 259 269
96. M. Studenovsky, R. Pola, M. Pechar, T. Etrych, K. Ulbrich, L. Kovar, M. Kabesova, and B. Rihova Polymer carriers for anticancer drugs targeted to EGF receptor Macromol. Biosci. 12 2012 1714 1720
97. P. Oberoi, R.A. Jabulowsky, H. Bähr-Mahmud, and W.S. Wels EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells PLoS ONE 8 2013 e61267 10.1371/journal.pone.0061267
98. Y. Gao, L. Chen, W. Gu, Y. Xi, L. Lin, and Y. Li Targeted nanoassembly loaded with docetaxel improves intracellular drug delivery and efficacy in murine breast cancer model Mol. Pharm. 5 2008 1044 1054
99. F. Zeng, H. Lee, and C. Allen Epidermal growth factor-conjugated poly (ethylene glycol)-block-poly (δ-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics Bioconjug. Chem. 17 2006 399 409
100. F.M. Mickler, L. Möckl, N. Ruthardt, M. Ogris, E. Wagner, and C. Bräuchle Tuning nanoparticle uptake: live-cell imaging reveals two distinct endocytosis mechanisms mediated by natural and artificial EGFR targeting ligand Nano Lett. 12 2012 3417 3423
101. J. Xu, F. Gattacceca, and M. Amiji Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice Mol. Pharm. 10 2013 2031 2044
102. X. Geng, H. Ye, Z. Feng, X. Lao, L. Zhang, J. Huang, and Z.R. Wu Synthesis and characterization of cisplatin-loaded, EGFR-targeted biopolymer and in vitro evaluation for targeted delivery J. Biomed. Mater. Res. A 100 2012 2839 2848
103. J. Zhang, W. Jin, X. Wang, J. Wang, X. Zhang, and Q. Zhang A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models Mol. Pharm. 7 2010 1159 1168
104. Y. Zhang, X. Wang, J. Wang, X. Zhang, and Q. Zhang Octreotide-modified polymeric micelles as potential carriers for targeted docetaxel delivery to somatostatin receptor overexpressing tumor cells Pharm. Res. 28 2011 1167 1178
105. N. Zheng, W. Dai, W. Du, H. Zhang, L. Lei, H. Zhang, X. Wang, J. Wang, X. Zhang, J. Gao, and Q. Zhang A novel lanreotide-encoded micelle system targets paclitaxel to the tumors with overexpression of somatostatin receptors Mol. Pharm. 9 2012 1175 1188
106. Y. Iwase, and Y. Maitani Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts Cancer Sci. 103 2012 310 316
107. Y. Iwase, and Y. Maitani Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma Mol. Pharm. 8 2011 330 337
108. Y. Xiang, L. Liang, X. Wang, J. Wang, X. Zhang, and Q. Zhang Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes J. Control. Release 152 2011 402 410
109. Y. Xiang, Q. Wu, L. Liang, X. Wang, J. Wang, X. Zhang, X. Pu, and Q. Zhang Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against the Parkinson's disease in the MPTP-induced mice model J. Drug Target. 20 2012 67 75
110. Z. Wang, Y. Yu, W. Dai, J. Lu, J. Cui, H. Wu, L. Yuan, H. Zhang, X. Wang, J. Wang, X. Zhang, and Q. Zhang The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer Biomaterials 33 2012 8451 8460
111. Z. Wang, Y. Yu, W. Dai, J. Cui, H. Wu, L. Yuan, H. Zhang, X. Wang, J. Wang, X. Zhang, and Q. Zhang A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth Biomaterials 34 2013 756 764
112. C. Reinemann, and B. Strehlitz Aptamer-modified nanoparticles and their use in cancer diagnostics and treatment Swiss Med. Wkly. 144 2014 w13908
113. J.R. Kanwar, J.S. Shankaranarayanan, S. Gurudevan, and R.K. Kanwar Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases Drug Discov. Today 2014 10.1016/j.drudis.2014.02.009
114. R. Bansal, J. Prakash, M. de Ruijter, L. Beljaars, and K. Poelstra Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis Mol. Pharm. 8 2011 1899 1909
115. D.I. Kang, S. Lee, J.T. Lee, B.J. Sung, J.Y. Yoon, J.K. Kim, J. Chung, and S.J. Lim Preparation and in vitro evaluation of anti-VCAM-1-Fab′-conjugated liposomes for the targeted delivery of the poorly water-soluble drug celecoxib J. Microencapsul. 28 2011 220 227
116. C.L. Modery-Pawlowski, and A.S. Gupta Heteromultivalent ligand-decoration for actively targeted nanomedicine Biomaterials 35 2014 2568 2579
117. P. Sapra, and T.M. Allen Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes Clin. Cancer Res. 10 2004 2530 2537
118. K. Laginha, D. Mumbengegwi, and T. Allen Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity Biochim. Biophys. Acta 1711 2005 25 32
119. J.M. Saul, A.V. Annapragada, and R.V. Bellamkonda A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers J. Control. Release 114 2006 277 287
120. S. Bhattacharyya, J.A. Khan, G.L. Curran, J.D. Robertson, R. Bhattacharya, and P. Mukherjee Efficient delivery of gold nanoparticles by dual receptor targeting Adv. Mater. 23 2011 5034 5038
121. K. Mack, R. Rüger, S. Fellermeier, O. Seifert, and R.E. Kontermann Dual targeting of tumor cells with bispecific single-chain Fv-immunoliposomes Antibodies 1 2012 199 214
122. R.C. Gunawan, and D.T. Auguste The role of antibody synergy and membrane fluidity in the vascular targeting of immunoliposomes Biomaterials 31 2010 900 907
123. R.C. Gunawan, and D.T. Auguste Immunoliposomes that target endothelium in vitro are dependent on lipid raft formation Mol. Pharm. 7 2010 1569 1575
124. A. Omolola Eniola, P. Jeanene Willcox, and D.A. Hammer Interplay between rolling and firm adhesion elucidated with a cell-free system engineered with two distinct receptor-ligand pairs Biophys. J. 85 2003 2720 2731
125. A. Omolola Eniola, and D.A. Hammer In vitro characterization of leukocyte mimetic for targeting therapeutics to the endothelium using two receptors Biomaterials 26 2005 7136 7144
126. E.A. Ferrante, J.E. Pickard, J. Rychak, A. Klibanov, and K. Ley Dual targeting improves microbubble contrast agent adhesion to VCAM-1 and P-selectin under flow J. Control. Release 140 2009 100 107
127. E. Kluza, D.W.J. van der Schaft, P.A.I. Hautvast, W.J.M. Mulder, K.H. Mayo, A.W. Griffioen, G.J. Strijkers, and K. Nicolay Synergistic targeting of αvβ3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis Nano Lett. 10 2010 52 58
128. Q. Xu, Y. Liu, S. Su, W. Li, C. Chen, and Y. Wu Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles Biomaterials 33 2012 1627 1639
129. Y. Li, H. He, X. Jia, W. Lu, J. Lou, and Y. Wei A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas Biomaterials 33 2012 3899 3908
130. J. Du, W. Lu, X. Ying, Y. Liu, P. Du, W. Tian, Y. Men, J. Guo, Y. Zhang, R. Li, J. Zhou, J. Lou, J. Wang, X. Zhang, and Q. Zhang Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals Mol. Pharm. 6 2009 905 917
131. C. Zhang, X. Wan, X. Zheng, X. Shao, Q. Liu, Q. Zhang, and Y. Qian Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice Biomaterials 35 2014 456 465
132. F. Pastorino, C. Brignole, D. Di Paolo, B. Nico, A. Pezzolo, D. Marimpietri, G. Pagnan, F. Piccardi, M. Cilli, R. Longhi, D. Ribatti, A. Corti, T.M. Allen, and M. Ponzoni Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy Cancer Res. 20 2006 10073 10082
133. J.S. Josan, H.L. Handl, R. Sankaranarayanan, L. Xu, R.M. Lynch, J. Vagner, E.A. Mash, V.J. Hruby, and R.J. Gillies Cellspecific targeting by heterobivalent ligands Bioconjug. Chem. 22 2011 1270 1278
134. L. Xu, J.S. Josan, J. Vagner, M.R. Caplan, V.J. Hruby, E.A. Mash, R.M. Lynch, D.L. Morse, and R.J. Gillies Heterobivalent ligands target cell-surface receptor combinations in vivo Proc. Natl. Acad. Sci. U. S. A. 109 2012 21295 21300
135. L. Xu, J. Vagner, J. Josan, R.M. Lynch, D.L. Morse, B. Baggett, H. Han, E.A. Mash, V.J. Hruby, and R.J. Gillies Enhanced targeting with heterobivalent ligands Mol. Cancer Ther. 8 2009 2356 2365
136. 3 Bioconjug. Chem. 25 2014 393 405
137. K.N. Sugahara, T. Teesalu, P.P. Karmali, V.R. Kotamraju, L. Agemy, D.R. Greenwald, and E. Ruoslahti Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Science 328 2010 1031 1035
138. Z. Zhua, C. Xie, Q. Liu, X. Zhen, X. Zheng, W. Wu, R. Li, Y. Ding, X. Jiang, and B. Liu The effect of hydrophilic chain length and iRGD on drug delivery from poly(ε-caprolactone)-poly(N-vinylpyrrolidone) nanoparticles Biomaterials 32 2011 9525 9535
139. L. Roth, L. Agemy, V.R. Kotamraju, G. Braun, T. Teesalu, K.N. Sugahara, J. Hamzah, and E. Ruoslahti Transtumoral targeting enabled by a novel neuropilin-binding peptide Oncogene 31 2012 3754 3763
140. Z. Wang, Y. Yu, and J. Ma LyP-1 modification to enhance delivery of artemisinin or fluorescent probe loaded polymeric micelles to highly metastatic tumor and its lymphatics Mol. Pharm. 9 2012 2646 2657
141. A. Eldar-Boock, D. Polyak, A. Scomparin, and R. Satchi-Fainaro Nano-sized polymers and liposomes designed to deliver combination therapy for cancer Curr. Opin. Biotechnol. 24 2013 682 689
142. A.R. Kirtane, S.M. Kalscheuer, and J. Panyam Exploiting nanotechnology to overcome tumor drug resistance: challenges and opportunities Adv. Drug Deliv. Rev. 65 2013 1731 1747
143. G. Gasparini, R. Longo, M. Fanelli, and B.A. Teicher Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions J. Clin. Oncol. 23 2005 1295 1311
144. W. Song, Z. Tang, D. Zhang, Y. Zhang, H. Yu, M. Li, S. Lv, H. Sun, M. Deng, and X. Chen Anti-tumor efficacy of c(RGDfK)-decorated polypeptide-based micelles co-loaded with docetaxel and cisplatin Biomaterials 35 2014 3005 3014
145. S. Barua, and S. Mitragotri Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles ACS Nano 7 2013 9558 9570
146. J. Gao, H. Chen, Y. Yu, J. Song, H. Song, X. Su, W. Li, X. Tong, W. Qian, H. Wang, J. Dai, and Y. Guo Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA Biomaterials 34 2013 10084 10098
147. X. Sun, Z. Pang, H. Ye, B. Qiu, L. Guo, J. Li, J. Ren, Y. Qian, Q. Zhang, J. Chen, and X. Jiang Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome Biomaterials 33 2012 916 924
148. Y.F. Zhang, J.C. Wang, D.Y. Bian, X. Zhang, and Q. Zhang Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies Eur. J. Pharm. Biopharm. 74 2010 467 473
149. W. Dai, W. Jin, J. Zhang, X. Wang, J. Wang, X. Zhang, Y. Wan, and Q. Zhang Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes Pharm. Res. 29 2012 2902 2911
150. F. Wang, D. Zhang, Q. Zhang, Y. Chen, D. Zheng, L. Hao, C. Duan, L. Jia, G. Liu, and Y. Liu Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel-polymer micelles to overcome multi-drug resistance Biomaterials 32 2011 9444 9456
151. Y.B. Patil, S.K. Swaminathan, T. Sadhukha, L. Ma, and J. Panyam The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance Biomaterials 31 2010 358 365
152. F. Zhao, H. Yin, and J. Li Supramolecular self-assembly forming a multifunctional synergistic system for targeted co-delivery of gene and drug Biomaterials 35 2014 1050 1062
153. S. Elsamany, and S. Abdullah Triple-negative breast cancer: future prospects in diagnosis and management Med. Oncol. 834 2014 10.1007/s12032-013-0834-y
154. Z.J. Deng, S.W. Morton, E. Ben-Akiva, E.C. Dreaden, K.E. Shopsowitz, and P.T. Hammond Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment ACS Nano 7 2013 9571 9584
155. N. Cao, D. Cheng, S. Zou, H. Ai, J. Gao, and X. Shuai The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells Biomaterials 32 2011 2222 2232
156. D. Cheng, N. Cao, J. Chen, X. Yu, and X. Shuai Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat Biomaterials 33 2012 1170 1179
157. Z. Xu, Z. Zhang, Y. Chen, L. Chen, L. Lin, and Y. Li The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model Biomaterials 31 2010 916 922
158. Y. Chen, J.J. Wu, and L. Huang Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy Mol. Ther. 18 2010 828 834
159. Y. Chen, S.R. Bathula, J. Li, and L. Huang Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer J. Biol. Chem. 285 2010 22639 22650
160. S. Sengupta, D. Eavarone, I. Capila, G. Zhao, N. Watson, T. Kiziltepe, and R. Sasisekharan Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system Nature 436 2005 568 572
161. J. Yao, L. Zhang, J. Zhou, H. Liu, and Q. Zhang Efficient simultaneous tumor targeting delivery of all-trans retinoid acid and paclitaxel based on hyaluronic acid-based multifunctional nanocarrier Mol. Pharm. 10 2013 1080 1091
162. Y. Mi, J. Zhao, and S.S. Feng Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer J. Control. Release 169 2013 185 192
163. Y. Wang, T. Yang, X. Wang, W. Dai, J. Wang, X. Zhang, Z. Li, and Q. Zhang Materializing sequential killing of tumor vasculature and tumor cells via targeted polymeric micelle system J. Control. Release 149 2011 299 306
164. T. Yang, Y. Wang, Z. Li, W. Dai, J. Yin, L. Liang, X. Ying, S. Zhou, J. Wang, X. Zhang, and Q. Zhang Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature Nanomedicine 8 2012 81 92
165. J. Zhao, Y. Mi, and S.S. Feng Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles Biomaterials 34 2013 3411 3421
166. Y. Xiao, R. Jaskula-Sztul, A. Javadi, W. Xu, J. Eide, A. Dammalapati, M. Kunnimalaiyaan, H. Chen, and S. Gong Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy Nanoscale 4 2012 7185 7193
167. X.B. Xiong, and A. Lavasanifar Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin ACS Nano 5 2011 5202 5213
168. C. Liu, F. Liu, L. Feng, M. Li, J. Zhang, and N. Zhang The targeted co-delivery of DNA and doxorubicin to tumor cells via multifunctional PEI-PEG based nanoparticles Biomaterials 34 2013 2547 2564
169. S. Liu, Y. Guo, R. Huang, J. Li, S. Huang, Y. Kuang, L. Han, and C. Jiang Gene and doxorubicin co-delivery system for targeting therapy of glioma Biomaterials 33 2012 4907 4916
170. J. Jiang, S.J. Yang, J.C. Wang, L.J. Yang, Z.Z. Xu, T. Yang, X.Y. Liu, and Q. Zhang Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin Eur. J. Pharm. Biopharm. 76 2010 170 178
171. Y. Liu, W.L. Lu, J. Guo, J. Du, T. Li, J.W. Wu, G.L. Wang, J.C. Wang, X. Zhang, and Q. Zhang A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes J. Control. Release 129 2008 18 25
172. Y. Zhang, H. Zhang, X. Wang, J. Wang, X. Zhang, and Q. Zhang The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles Biomaterials 33 2012 679 691
173. D.B. Kirpotin, D.C. Drummond, Y. Shao, M.R. Shalaby, K. Hong, U.B. Nielsen, J.D. Marks, C.C. Benz, and J.W. Park Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models Cancer Res. 66 2006 6732 6740
174. D.W. Bartlett, H. Su, I.J. Hildebrandt, W.A. Weber, and M.E. Davis Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measur Proc. Natl. Acad. Sci. U. S. A. 104 2007 15549 15554
175. K.F. Pirollo, and E.H. Chang Does a targeting ligand influence nanoparticle tumor localization or uptake Trends Biotechnol. 26 2008 552 558
176. S. Hussain, A. Plückthun, T.M. Allen, and U. Zangemeister-Wittke Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system Mol. Cancer Ther. 6 2007 3019 3027
177. O.C. Farokhzad, and R. Langer Impact of nanotechnology on drug delivery ACS Nano 3 2009 16 20
178. B.R. Caré, and H.A. Soula Impact of receptor clustering on ligand binding BMC Syst. Biol. 5 2011 48 (http://www.biomedcentral.com/1752-0509/5/48)
179. A. Wei, J.G. Mehtala, and A.K. Patri Challenges and opportunities in the advancement of nanomedicines J. Control. Release 164 2012 236 246
180. I.K. Kwon, S.C. Lee, B. Han, and K. Park Analysis on the current status of targeted drug delivery to tumors J. Control. Release 164 2012 108 114